Type
Internal restructuring
Country
France
Region
île de France; Val-de-Marne;
Location of affected unit(s)
Vitry-sur-Seine
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

330 - 471 jobs
Number of planned job losses
Job loss
106 jobs
Number of planned job creations
Job creation
Announcement Date
1 April 2008
Employment effect (start)
1 May 2008
Foreseen end date
31 December 2012

Description

The French pharmaceuticals group Sanofi-Aventis has announced that it is to cut up to 471 jobs (between the half of the total employees and 471 jobs according to the unions and the direction) at its production plant in the French city of Vitry-sur-Seine (south-east of Paris) in order to turn the site into a biotech manufacturing facility specialized in cellular therapy. The site will, however, retain the production of antineoplastic. The Group will invest 100 million-euro in this project, and some employees affected should avail of early retirement, or internal redeployment.

This restructuring, the biggest since the merger in 2004, will last until 2012 and relocate the production of drugs to the group’s other manufacturing outposts in France, Germany and Italy. Moreover, if the management foresees some job creation (about 106) within the new site, there will also be the loss of some 300 jobs among subcontractors.


Sources

  • 1 April 2008: Le Figaro
  • 2 April 2008: Libération
  • 1 April 2008: Les Echos
  • 2 April 2008: Le Monde

Citation

Eurofound (2008), Sanofi-Aventis, Internal restructuring in France, factsheet number 66470, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/66470.